Boissin, Constance
Wang, Yinxi
Sharma, Abhinav
Weitz, Philippe
Karlsson, Emelie
Robertson, Stephanie
Hartman, Johan
Rantalainen, Mattias
Funding for this research was provided by:
Karolinska Institute
Article History
Received: 21 December 2023
Accepted: 15 May 2024
First Online: 3 June 2024
Declarations
:
: The study has approval from the Swedish Ethical Review Authority (2017/2106-31, with amendments 2018/1462-32 and 2019–02336).
: The authors declare the following financial interests or personal relationships which may be considered as potential competing interests: JH has obtained speaker’s honoraria or advisory board remunerations from Roche, Novartis, AstraZeneca, Eli Lilly, MSD and Gilead. JH has received institutional research grants from Cepheid, Roche, Novartis and AstraZeneca. MR and JH are co-founders and shareholders of Stratipath AB. EK is employed by Stratipath AB. YW, PW and SR are employed by Stratipath AB and hold employee stock options. All remaining authors have declared no conflicts of interest.